| 10365-5 |
Cotinine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cotinine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
10365-5 |
|
|
|
|
Both |
|
|
|
0 |
Cotinine SerPl-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Nicotine metabolite; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0i |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 103650-8 |
Lutropin^4H post dose gonadotropin releasing hormone |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Lutropin [Units/volume] in Serum or Plasma --4 hours post dose gonadotropin releasing hormone |
|
ADD |
DefinitionDescription |
|
|
U/L |
|
|
|
|
|
|
CHAL |
|
103650-8 |
|
|
|
|
|
|
|
|
0 |
LH 4h p GnRH SerPl-aCnc |
|
|
|
N |
|
4h p GnRH; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; GHR; GnRH; Horm; ICSH; Interstitial cell-stimulating hormone; Interstitual cell stimulating hormone; Leutinizing hormone; LH; LHRH; Luliberin; Luteinizing hormone; Luteinizing hormone releasing hormone; Lutenin; Lutenizing hormone; Lutropin release factor; Lutropin^4H p dose GnRH; Ovulation test; p dose; p GnRH; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.77 |
|
|
|
|
|
|
|
U/L |
|
|
|
0 |
| 103651-6 |
Atomoxetine |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Atomoxetine [Presence] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/ml |
|
|
|
|
|
|
DRUG/TOX |
|
103651-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Atomoxetine Ur Ql Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Strattera; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 103652-4 |
4-Hydroxyatomoxetine |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
4-Hydroxyatomoxetine [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/ml |
|
|
|
|
|
|
DRUG/TOX |
|
103652-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
4OH-atomoxetine Ur Cfm-mCnc |
|
|
|
N |
|
4OH-atomoxetine; Atomoxetine metabolite; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Strattera metabolite; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 103653-2 |
Ciprofloxacin |
Susc |
Isolate.meningitis |
Pt |
OrdQn |
|
|
ACTIVE |
Ciprofloxacin [Susceptibility] for meningitis |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
103653-2 |
|
|
|
|
Both |
|
|
|
0 |
Ciprofloxacin Susc Islt.mening |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; c250; c307; C81; Ciloxan; Cipro; Ciprofloxacn; Ciprofloxin; Islt; Islt.mening; Isol; Mening; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103654-0 |
Meropenem |
Susc |
Isolate.meningitis |
Pt |
OrdQn |
|
|
ACTIVE |
Meropenem [Susceptibility] for meningitis |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
103654-0 |
|
|
|
|
Both |
|
|
|
0 |
Meropenem Susc Islt.mening |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Islt.mening; Isol; Mening; Meronem; Merrem; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103655-7 |
Observation |
Color |
Plr fld.spun |
Pt |
Nom |
|
|
ACTIVE |
Color of Spun Pleural fluid |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
103655-7 |
|
|
|
|
Both |
|
|
|
0 |
Color spun Plr |
|
|
|
N |
|
Nominal; Pleural; Pleural fluid; Point in time; Random; SPEC; spun Plr; Supernat; Supernate; thoracentesis fluid |
2.79 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |
| 103656-5 |
Observation |
Color |
Periton fld.spun |
Pt |
Nom |
|
|
ACTIVE |
Color of Spun Peritoneal fluid |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
103656-5 |
|
|
|
|
Both |
|
|
|
0 |
Color spun Prt |
|
|
|
N |
|
Ascites; Ascitic fluid; Ascitis; Nominal; Peritoneal fluid; Point in time; Prt; Random; SPEC; spun Prt; Supernat; Supernate |
2.79 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |
| 103657-3 |
Observation |
Color |
Pericard fld.spun |
Pt |
Nom |
|
|
ACTIVE |
Color of Spun Pericardial fluid |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
103657-3 |
|
|
|
|
Both |
|
|
|
0 |
Color spun Pcar |
|
|
|
N |
|
Nominal; PCAR; Pericardial Fluid; Point in time; Random; SPEC; spun Pcar; Supernat; Supernate |
2.79 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |
| 103659-9 |
Cells.chromosome Y deletion/Cells counted |
NFr |
Bld/Bone mar |
Pt |
Qn |
FISH |
|
ACTIVE |
Cells.chromosome Y deletion/Cells counted in Blood or Marrow by FISH |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
MOLPATH.DELDUP |
|
103659-9 |
|
FISH |
|
|
Both |
|
|
|
0 |
Cells.chrom Y Del/Cells NFr Bld/Mar FISH |
|
|
|
N |
|
Bld/Mar; Blood; BM; BON; Bone marrow; Cell; Cells.chrom Y; Cellularity; Chromosom; Chromosomes; Del; Deletions; Fluorescent in situ hybridization; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Molecular pathology; MOLPATH; MOLPATH.DELDUP; Number Fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood; Whole blood or Bone marrow |
2.77 |
2.77 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 10366-3 |
Cotinine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Cotinine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
10366-3 |
|
|
|
|
Both |
|
|
|
0 |
Cotinine Ur-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Nicotine metabolite; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UniversalLabOrders; UR; Urn |
2.73 |
1.0i |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 103660-7 |
Entamoeba coli DNA |
PrThr |
Stool |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Entamoeba coli DNA [Presence] in Stool by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103660-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Entamoeba coli DNA Stl Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amoeba; Amplif; Amplification; Amplified; Bowel movement; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Faecal; Faeces; Fecal; Feces; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Stl; Stool = Fecal; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.79 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: EXAMPLE_UNITS: Removed invalid example units; |
0 |
| 103661-5 |
Campylobacter & Salmonella & Shigella sp |
Prid |
Stool |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Campylobacter and Salmonella and Shigella sp identified in Stool by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103661-5 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Camp & Sal & Shig sp Stl Cult |
|
|
|
N |
|
Bowel movement; C&S; Camp & Sal & Shig sp; Campy; Cult; Cultures; Faecal; Faeces; Fecal; Feces; Identity or presence; Microbiology; Nominal; Point in time; Random; Sal; Salm + Shig; Salmonel; Shigellosis; Spec; species; spp; Stl; Stool = Fecal |
2.79 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 103662-3 |
Campylobacter & Salmonella & Shigella & Yersinia sp |
Prid |
Stool |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Campylobacter and Salmonella and Shigella and Yersinia sp identified in Stool by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103662-3 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Camp, Sal, Shig,Yers sp Stl Cult |
|
|
|
N |
|
Bowel movement; C&S; Camp, Sal, Shig,Yers sp; Campy; Cult; Cultures; Faecal; Faeces; Fecal; Feces; Identity or presence; Microbiology; Nominal; Point in time; Random; Sal; Salmonel; Shigellosis; Spec; species; spp; Stl; Stool = Fecal |
2.79 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 103663-1 |
Salmonella & Shigella & Campylobacter & E. coli sp |
Prid |
Stool |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Salmonella and Shigella and Campylobacter and E. coli sp identified in Stool by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103663-1 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Sal, Shige, Camp, E. coli sp id Stl Cult |
|
|
|
N |
|
Bowel movement; C&S; Campy; Cult; Cultures; Faecal; Faeces; Fecal; Feces; Identity or presence; Microbiology; Nominal; Point in time; Random; Sal; Sal, Shige, Camp, E. coli sp id; Salmonel; Shigellosis; Spec; species; spp; Stl; Stool = Fecal |
2.79 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 103664-9 |
Dehydronorketamine |
MCnc |
Urine |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Dehydronorketamine [Mass/volume] in Urine by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/ml |
|
|
|
|
|
|
DRUG/TOX |
|
103664-9 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Dehydronorketamine Ur LC/MS/MS-mCnc |
|
|
|
N |
|
5,6-dehydronorketamine; DHNK; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 103665-6 |
Cells.CD4+CD26-/Cells.CD4 |
NFr |
Bld |
Pt |
Qn |
Flow cytometry |
|
ACTIVE |
CD4+ CD26- Cells/CD4 cells in Blood by Flow cytometry (FC) |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
103665-6 |
|
Flow cytometry |
|
|
Both |
|
|
|
0 |
CD4+CD26- Cells/CD4 Cells NFr Bld FC |
|
|
|
N |
|
ADA-binding protein; Adenosine deaminase-binding protein; Blood; CD4 Cells; CD4+CD26- Cells; Cell; CELL MARKERS; Cellularity; Dipeptidylpeptidase IV; DPP IV; Dynamic; Ectoenzyme; FC; Helper T cells; Inducer T cells; L3T4; Leu3; Leu-3; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; T4; T-4; W3/25; WB; Whole blood |
2.79 |
2.77 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 103666-4 |
Cells.CD200/Cells |
NFr |
Bone marrow |
Pt |
Qn |
Flow cytometry |
|
ACTIVE |
Cells.CD200/cells in Bone marrow by Flow cytometry (FC) |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
103666-4 |
|
Flow cytometry |
|
|
Both |
|
|
|
0 |
Cells.CD200 NFr BM FC |
|
|
|
N |
|
BM; BON; Cell; CELL MARKERS; Cellularity; Dynamic; FC; Number Fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.79 |
2.77 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 103667-2 |
Cells.chromosome region 1p32 deletion/Cells counted |
NFr |
Bld/Bone mar |
Pt |
Qn |
FISH |
|
ACTIVE |
Cells.chromosome region 1p32 deletion/Cells counted in Blood or Marrow by FISH |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
MOLPATH.DELDUP |
|
103667-2 |
|
FISH |
|
|
Both |
|
|
|
0 |
Clls.chrm rg 1p32 Dl/Clls NFr Bld/Mr FSH |
|
|
|
N |
|
Bld/Mar; Blood; BM; BON; Bone marrow; Cell; Cells.chrom rg 1p32; Cellularity; Chromosom; Chromosomes; Cyto loc; Del; Deletions; Fluorescent in situ hybridization; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Molecular pathology; MOLPATH; MOLPATH.DELDUP; Number Fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood; Whole blood or Bone marrow |
2.77 |
2.77 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 103668-0 |
Gabapentin |
PrThr |
TissCo |
Pt |
Ord |
Screen |
|
ACTIVE |
Gabapentin [Presence] in Cord tissue by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
103668-0 |
|
Screen |
|
|
Both |
|
|
|
0 |
Gabapentin TissCo Ql Scn |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Horizant; Neurontin; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103669-8 |
Mitragynine |
PrThr |
TissCo |
Pt |
Ord |
Screen |
|
ACTIVE |
Mitragynine [Presence] in Cord tissue by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
103669-8 |
|
Screen |
|
|
Both |
|
|
|
0 |
Mitragynine TissCo Ql Scn |
|
|
|
N |
|
7-hydroxymitragynine; DRUG/TOXICOLOGY; Drugs; Kratom; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 10367-1 |
Ethanol |
MCnc |
Gast fld |
Pt |
Qn |
|
|
ACTIVE |
Ethanol [Mass/volume] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
DRUG/TOX |
|
10367-1 |
|
|
|
|
Both |
|
|
|
0 |
Ethanol Gast-mCnc |
|
|
|
Y |
|
Alc; Alcohol; DRUG/TOXICOLOGY; Drugs; Ethyl alcohol; EtOH; GAST; Gastric contents; Gastric fluid; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.34 |
1.0i |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 103670-6 |
Gabapentin |
PrThr |
TissCo |
Pt |
Ord |
Confirm |
|
ACTIVE |
Gabapentin [Presence] in Cord tissue by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
103670-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Gabapentin TissCo Ql Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; Horizant; LC/MS/MS; Neurontin; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103671-4 |
Mitragynine |
PrThr |
TissCo |
Pt |
Ord |
Confirm |
|
ACTIVE |
Mitragynine [Presence] in Cord tissue by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
103671-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Mitragynine TissCo Ql Cfm |
|
|
|
N |
|
7-hydroxymitragynine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; Kratom; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103672-2 |
Amoxicillin+Clavulanate |
Susc |
Isolate.UTI |
Pt |
OrdQn |
|
|
ACTIVE |
Amoxicillin+Clavulanate [Susceptibility] for UTI |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
103672-2 |
|
|
|
|
Both |
|
|
|
0 |
Amoxicillin+Clav Susc Islt.UTI |
|
|
|
N |
|
Amox; Amoxicillin+clavulanic acid; Amoxicilloyl; Amoxil; ANTIBIOTIC SUSCEPTIBILITIES; AST; Augmentin; Bristamox; c204; c305; c6; Clav; Clavate; Clavu; Clavul; Clavulanic; Clavulanic acid; Islt; Islt.UTI; Isol; Larotid; Moxalin; Moxicillin+clavulanic acid; Point in time; Polymox; Random; Sumox; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Trimox; Wymox |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
